Avascular necrosis (AVN) of the talus is a debilitating condition, often leading to arthritis and arthrosis of the subtalar and ankle joints. There are three basic categories of cause for AVN. Approximately 10% of AVN of the talus is considered idiopathic: 15% is medication induced and 75% from trauma. The most feared complication of talar injuries is AVN.
In this clinical case, a 57-year-old white female afflicted with rheumatoid arthritis received treatment for a 35-degree interphalangeal (IP) thumb joint deviation. The thumb deviation clinically described as a boutonniere (French for buttonhole) deformity was treated with a combination of Prolotherapy and splinting. She wore a custom three-point splint for six weeks and received three separate Prolotherapy treatments within that six-week period. After treatment, the deviation decreased from 35 degrees to 10 degrees, and her thumb pain decreased from 7 to 1 on a pain scale of 10 as the highest level.
The scope of practice for the treatment of the ligamentous, capsular and fascial tissues by Manual Therapists (Massage Therapy) limits the therapist to utilizing their hands along with active patient participation.
Pain management and the resolution of that pain has become the campaign of the current veterinary and pet owner communities. The fastest growing segment of our pet population is the aging dog and cat. Prolotherapy is one of the oldest, yet little known, modalities for resolution of pain and lameness. Prolotherapy is compared to its pharmacologic and surgical counterparts. This paper contrasts the current practices available for the resolution of common (ACL) knee injuries and (HD) hip dysplasia in the veterinary community. ACL injuries and HD are the two most prevalent and costly pathologies in modern veterinary practices across America. The science of Prolotherapy is brought into focus and compared with conventional solutions for soft tissue injuries and osteoarthritis. The objective of this paper is to make a case for Prolotherapy and emphasize its usage and application in veterinary medicine.
In the past 10 years, biocellular regenerative medicine has recognized the potential value and availability of a heterogeneous, undifferentiated, nucleated cell population with the adipose tissue complex (ATC). With the recognition of higher mesenchymal stem cell concentrations, ease and safety of access, and the very heterogeneous undifferentiated cell populations in the native 3D adipose matrix, many researchers and clinicians are moving from bone marrow sources to the adipose complex.